Tibotec Pharmaceuticals has entered into an agreement with Gilead Sciences for the development and commercialisation of a new once-daily fixed-dose antiretroviral.
The complete once-daily antiretroviral treatment regimen for HIV contains Tibotec’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25mg) and Gilead’s Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg).
Tibotec R&D president Roger Pomerantz said that a simplified regimen may help improve patient adherence and decrease overall pill burden.
“We are very pleased to collaborate with Gilead, one of the leading companies in the fight against HIV/AIDS, and look forward to advancing this new fixed-dose product in addition to TMC278 as a single agent,” Pomerantz said.
Tibotec is currently studying the combination of Truvada and TMC278 in a Phase III programme through two ongoing clinical trials, TMC278-C209 and TMC278-C215, which have enrolled over 1,300 treatment-naive adult patients with HIV-1.